Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators

Haitao Sun  
Department of Interventional Radiology, Zhongshan hospital, Fudan university, Shanghai institute of Medical imaging

Tianzhu Yu  
Department of Interventional Radiology, Zhongshan hospital, Fudan university, Shanghai institute of medical imaging

Xin Li  
institute for technical and macromolecular Chemistry, RWTH Aachen University

Yangyang Lei  
Department of Interventional Radiology, Zhongshan hospital, Fudan university, Shanghai institute of Medical imaging

Jianke Li  
Department of Interventional Radiology, Zhongshan hospital, Fudan university, Shanghai institute of Medical imaging

Xiuahui Wang  
institute of translational medicine, Shanghai university

Peike Peng  
Shanghai University of Traditional Chinese Medicine, school of basic sciences

Dalong Ni  
Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai institute of traumatology and orthopaedics, Rujin hospital, Shanghai jiao tong university School of Medicine

Xiaolin Wang  
Department of Interventional Radiology, Zhongshan hospital, Fudan university, Shanghai institute of medical imaging

Yu Luo  
Shanghai University of Engineering Science  
https://orcid.org/0000-0002-7088-0715
Abstract

Background

The construction of a nanoimmune controlled-release system that spatiotemporally recognizes tumor lesions and stimulates the immune system response step by step is one of the most potent cancer treatment strategies for improving the sensitivity of immunotherapy response.

Results

Here, a composite nanostimulator (CNS) was constructed for the release of second near-infrared (NIR-II) photothermal-mediated immune agents, thereby achieving spatiotemporally controllable photothermal-synergized immunotherapy. CNS nanoparticles comprise thermosensitive liposomes as an outer shell and are internally loaded with an NIR-II photothermal agent, copper sulfide (CuS), toll-like receptor-9 (TLR-9) agonist, cytosine-phospho-guanine oligodeoxynucleotides, and programmed death-ligand 1 (PD-L1) inhibitors (JQ1). Following NIR-II photoirradiation, CuS enabled the rapid elevation of localized temperature, achieving tumor ablation and induction of immunogenic cell death (ICD) as well as disruption of the lipid shell, enabling the precise release of two immune-therapeutical drugs in the tumor region. Combining ICD, TLR-9 stimulation, and inhibited expression of PD-L1 allows the subsequent enhancement of dendritic cell maturation and increases infiltration of cytotoxic T lymphocytes, facilitating regional antitumor immune responses.

Conclusion

CNS nanoparticle-mediated photothermal-synergized immunotherapy efficiently suppressed the growth of primary and distant tumors in two mouse models and prevented pulmonary metastasis. This study thus provides a novel sight into photo-controllably safe and efficient immunotherapy.

Background

Tumor immunotherapy that mobilizes immune cells to fight malignant tumors is a promising therapeutic approach[1, 2]. Diverse immunotherapy strategies, such as the modulation of immune checkpoint inhibitors (ICBs) against programmed death/ligand 1 (PD-1/PD-L1) [3, 4], cytotoxic T lymphocyte-associated protein 4 (CTLA-4) [5, 6], and adoptive T cell transfer [7–9], have shown satisfactory prospects in clinical studies. Several immune drugs, such as PD-L1 inhibitors and CTLA-4 inhibitors, have been approved by the U.S. Food and Drug Administration (FDA) and successfully commercialized[10]. However, immunotherapy for clinical application has only benefited a small proportion of specific tumor patients due to a low immune response[11, 12]. For instance, tumor patients with an abnormal immune status rarely benefit from checkpoint blockade treatment[13]. Moreover, patients with solid tumors cannot easily be treated using chimeric antigen receptor redirected T lymphocytes, which only benefit some...
patients with hematological cancers[14–16]. Other major limiting factors of tumor immunotherapy include serious immune-related systemic toxicity caused by the action of immune drugs in normal tissues and the low efficiency of immune activation in solid tumors[17]. Therefore, the use of clinical immunotherapy with higher efficiency and safety is necessary.

Nanomedicines combining nanotechnology and immunotherapy have shown the potential to improve the efficacy of immunotherapy and minimize toxic side effects[18, 19]. The therapeutic efficiency of nanomedicine-mediated immunotherapy can be strengthened by optimization of pharmacokinetics and toxicity of traditional immune-drugs and improving the intratumoral concentration of drugs[20, 21]. Additionally, immunotherapeutic nanomedicines remolded with nanoengineering technology can also improve the efficiency of immune activation via several other mechanisms, such as controlling the timing of immune drug release and/or activation[22], actively targeting immune cells[23, 24], and optimizing the efficiency of drug internalization[25]. These nanomedicines can be designed to respond to external energy fields, such as light[26], ultrasound[27], and magnetic fields[28], thereby achieving the high spatial-temporally release of immune-drugs in specific regions. Li et al. recently developed an activatable engineered immune-device, which can be remotely controlled by near-infrared (NIR) light. In this scenario, NIR light excitation was used to break the photoresponsive linker, releasing active CpG oligonucleotides (ODNs) and precisely activating local intratumoral inflammation without obvious systemic side effects[29]. Therefore, steerable nanomedicines that precisely and safely control cancer immunotherapy are highly promising.

Photothermal therapy (PTT) can act based on the host-guest effect between the laser and material in addition to its familiar high-temporal resolution regulation of drug release and photothermal ablation of tumors[30–32]. The nanomedicine-mediated photothermal effect can ablate tumor cell release of tumor antigens, damage-associated molecular patterns (DAMPs), and immunostimulatory elements, which enable the maturation of dendritic cells (DCs) and activation of immune cells[33–35]. In addition to synergistic effects with immunotherapy, the photothermal effect generated by PTT can also be used to trigger the release of immune agents from nanocarriers by melting the temperature-responsive chemical bonds or nanocarrier structures[36]. Thus, PTT-synergized immunotherapy has great potential to achieve more accurate, effective, and safe immune activation against tumor growth. Sun et al. recently constructed an injectable lipid gel encapsulating a photothermal agent (IR820) and anti-PD-L1 antibody (aPD-L1), which enabled the controllable release of aPD-L1 in specific areas, achieving photothermal-assisted immunotherapy[37]. To date, the combined use of PTT with immunotherapy has mostly been based on the excitation of light in the first NIR window (NIR-I, 700–1000 nm), which has inherent limitations of relatively low tissue penetration depth (≤ 1 cm)[38]. Comparatively, in terms of light penetration, the light in the second NIR window (NIR-II, 1000–1700 nm) was elevated three to five-fold (3–5 cm)[39–41]. Phototoxicity analysis showed that the maximum permissible exposure (MPE) of NIR-II light for skin was improved compared with NIR-I light. For example, the MPE of 1064 nm NIR-II light (1 W cm⁻²) was around three-fold higher than that of 808 nm NIR-I light (0.33 cm⁻²)[42]. Therefore, NIR-II PTT-
synergized immunotherapy may yield better immune-activating effects in the deeper tissues of patients with solid tumors.[43]. However, few studies have investigated NIR-II PTT-activated immunotherapy.

In the present study, different types of novel NIR-photoactivated composite nanostimulator (CNS) were constructed for NIR-II photothermal-synergized immunotherapy. The CNS nanoparticles internally contained copper sulfide (CuS), a NIR-II photothermal conversion agent, two types of immune agent, CpG ODNs, a toll-like receptor-9 (TLR-9) agonist, and JQ1, a PD-L1 inhibitor, which was externally encapsulated by a temperature-sensitive lipid shell (Scheme 1). CuS nanoparticles have recently been considered to be excellent NIR-II photothermal conversion agents due to their obvious absorbance in the NIR-II window, high stability, and good biocompatibility, and have been applied to tumor treatment. The temperature-sensitive lipid shell consisted of thermally sensitive 1,2-dipalmitoyl-sn-glycerol-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol)2000 (DSPE–PEG2k), and could be melted at a relatively high temperature (> 41°C, the phase transition temperature of DPPC), thereby releasing loaded immune drugs into a specific region.[44, 45]. CpG, which is a well-known immunoadjuvant studied in phase I-III trials, can facilitate the activation of DCs and enhance cytokine secretion by antigen-presenting cells (APCs).[46, 47]. JQ1, which is a bromodomain and extraterminal protein BRD4 inhibitor, was used to overcome immunological tolerance by downregulating the intratumoral expression of PD-L1.[48]. However, the clearance properties of CpG and potential drug toxicity and water insolubility of JQ1 are limited in their applications for tumor treatment. Thus, the present study used two immune drugs encapsulated in thermally-sensitive liposomes, which were intravenously administered for delivery into the tumor site without being prematurely cleared or released elsewhere. NIR-II photoexcitation of the tumor site enabled CNS-mediated NIR-II PTT to elevate the intratumoral temperature, leading to tumor ablation as well as ICD of tumor cells and releasing of immune-related molecules. Notably, PTT-mediated hyperthermia was able to disrupt the thermally-sensitive lipid layer for the spatiotemporally controllable release of immune agents in the tumor region. Combining ICD and stimulation of TLR-9 are potent promoters of DC maturation in tumor-draining lymph nodes, resulting in an adaptive antitumor immune response. JQ1 can further enhance the intratumoral infiltration of cytotoxic T lymphocytes via downregulation of PD-L1 expression to achieve a more robust antitumor immune activation. CNS nanoparticle-mediated NIR-II photothermal-synergized immunotherapy not only efficiently suppressed the growth of both primary and distant tumors but also greatly inhibited pulmonary metastasis in a murine breast cancer model.

**Material And Methods**

**Synthesis of BSA–CuS nanoparticles**

The synthetic process was briefly divided into three steps. First, CuCl2 (0.1 M) dispersed in 2 mL of ultrapure water was added dropwise into BSA (250 mg) dispersed in 50 mL of ultrapure water and reacted for 3 min. Then, NaOH (2 M) was rapidly infused into the mixed solution and stirred for 3 min. Finally, Na2S (0.5 M) dispersed in 0.8 mL ultrapure water was rapidly added to the mixed solution. The solution was mixed using magnetic stirring for 3 h. The obtained BSA-CuS solution was purified by
centrifugation at 12,000 rpm for 5 min. The supernatant was then dialyzed against water using a dialysis bag (molecular weight cutoff of 8–14 kDa). The purified BSA-CuS nanoparticles (referred to as CuS) were then stored at 4°C prior to use.

**Synthesis of photoactivated CNS.**

DSPE-PEG$_{2k}$, DPPC, and JQ1 with a mass ratio of 5:25:1 were co-dissolved in 10 mL chloroform. The mixture solution was then evaporated to form a thin film using a rotary evaporator. Next, 20 mL of ultrapure water containing CuS (2 mg) and CpG (2 OD) was added into the thin film and stirred at 55°C for 1 h. After the hydration process, the solution was sonicated in ice bath conditions for 60 min. The obtained solutions were then filtered using a 0.22-μm PVDF syringe-driven filter (Millipore, Bedford, USA) and then purified using ultrafiltration (cutoff molecular weight of 50,000 Da, 5,000 rpm) three times to remove unloaded drugs. The obtained CNS$_D$ (CuS-CpG-JQ1@lipsome) was stored at 4°C prior to use. CNS$_0$ (CuS@lipsome), CNS$_C$ (CuS-CpG@lipsome), and CNS$_J$ (CuS-JQ1@lipsome) were synthesized using the same method. Additionally, ICG-loaded liposomes were constructed for cellular uptake assays in vitro and NIR fluorescence imaging in vivo. ICG@CNS$_D$ was synthesized similarly using the hydration-sonication procedure. In brief, DSPE-PEG$_{2k}$, DPPC, and JQ1 with a mass ratio of 5:25:1 were co-dissolved in chloroform. A thin film was obtained through a rotary evaporator. Then, 20 mL ultrapure water containing ICG (2 mg), CuS (2 mg), and CpG (2 OD) and was added into the above thin film, and stirred at 55°C for 1 h. The subsequent synthesis method was the same as those of CNS$_D$. Similarly, ICG@CNS$_0$, ICG@CNS$_C$, and ICG@CNS$_J$ were also obtained through the same method.

The CNS nanoparticle morphologies were imaged using JEM 2100F transmission electron microscope. The DLS and zeta potential of the obtained CNS nanoparticles were analyzed using the Zetasizer Nano series. UV-vis spectrophotometry and HPLC were performed to investigate the loading capacity (LC) and encapsulation efficiency (EE) of CuS, CpG (Cy5.5-CpG, absorbance peak = 650 nm) and JQ1 ($\lambda_{abs} = 260$ nm, elution ~ 10 min) of CNS$_D$. The colloidal stability of CNS$_D$ nanoparticles was evaluated using the Zetasizer Nano series. CNS$_D$ dissolved in 1 × PBS was continuously observed for 10 days, and the corresponding DLS and PDI of the nanoparticles were recorded every two days.

**Cellular uptake of CNS nanoparticles**

ICG-loaded CNS nanoparticles were used to study the uptake of nanoparticles in Panc02 cells. The Panc02 cells were seeded in 12-well plates at a density of $2 \times 10^5$ per well overnight and then co-cultured with ICG@CNS$_D$, ICG@CNS$_C$, ICG@CNS$_J$, and ICG@CNS$_D$ for 24 h (20 μg mL$^{-1}$ for all). Cells were then washed three times with PBS and collected to measure the intracellular fluorescence intensity of ICG via flow cytometry.

**Cytotoxicity assays and evaluation of therapeutic efficacy in vivo**
The safety performance of the nanoparticles were evaluated in vivo. Panc02 cells were plated in 96-well plates and cultured overnight and then co-cultured with CNS₀, CNS₇, CNS₉, and CNS₉ at various CuS concentrations (0, 12.5, 25, 50, and 100 μg mL⁻¹) for 24 h. The cells were then washed three times with PBS and the absorbance of each well was measured at 450 nm using a microplate reader to examine cell viability. The viabilities of various CNS nanoparticles and laser-treated cells were subsequently verified using CCK-8 assays. Panc02 cells were incubated in 96-well plates overnight and then co-cultured with CNS₀, CNS₇, CNS₉, and CNS₉ at various CuS concentrations (0, 12.5, 25, 50, and 100 μg mL⁻¹) for 24 h. The cells were then rinsed three times with PBS and a new medium was added. Each well was irradiated using a 1064 nm laser (1 W cm⁻²) for 5 min and then cultured for 24 h. Finally, the absorbance of each well was measured at 450 nm using a microplate reader.

**In vivo tumor accumulation of CNS nanoparticles**

Panc02 tumor-bearing C57BL/6 mice (n = 3) were systemically injected with 0.2 mL of 300 μg/mL CNS@ICG via tail-vein injection. The mice were imaged at different post-injection time points (0, 8, 24, and 36 h) to determine the accumulation of CNS nanoparticles in the tumor. The tumors were imaged using the IVIS imaging system (excitation and emission at 710 and 790 nm, respectively). The corresponding processing software (Living Image software) was performed to record images and calculate the fluorescence intensity of tumors at different time points.

**In vivo photothermal performance of CNS nanoparticles**

Panc02 tumor-bearing C57BL/6 mice were randomly divided into four groups (n = 3). The mice in each group were administered with 300 μg/mL CNS₀, CNS₇, CNS₉, and CNS₉ via tail-vein injection (0.2 mL). Each primary tumor was then photoirradiated using a 1064 nm laser (1 W cm⁻²) for 5 min at 24 h post-injection. The thermal images and corresponding temperature of tumors were recorded using an infrared thermal camera (FLIR 225s IR thermal).

**In vivo curative effect assessment on Panc02 tumor models**

Panc02 tumor-bearing C57BL/6 mice were randomly divided into six groups: control (PBS); CNS₀ + L; CNS₇ + L; CNS₉ + L; CNS₉ + L; and CNS₉ + L (n = 5). The mice in each group were intravenously administered with 0.2 mL PBS or 300 μg/mL CNS₀, CNS₇, CNS₉, and CNS₉. Then, each primary tumor was photoirradiated using a 1064-nm laser (1 W cm⁻²) for 5 min at 24 h post-injection. After the different treatments, the treatment efficacies were assessed by calculating the volumes of the primary and distant tumors every two days for 14 days. Meanwhile, the body weights of Panc02 tumor-bearing C57BL/6 mice were also recorded every two days for 14 days. Tumor volume (V) was calculated using the formula: \( V = \text{length} \times \text{width}^2 / 2 \), and the relative tumor volumes were calculated as \( V / V_0 \) (where \( V_0 \) represents the original tumor volumes). On day 1 post-treatment, the primary tumors were examined for H&E, TUNEL, and Ki-67 staining to evaluate the intratumoral treatment effect. On day 14 post-treatment, the mice in
each group were euthanized and the corresponding tumor weights of both the primary and distant tumors were calculated.

**In vivo treatment and antimetastatic efficacy evaluation on 4T1 tumor models**

4T1 tumor-bearing Balb/c mice were randomly divided into six groups: control (PBS); CNS₀ + L; CNS₉ + L; CNS_J + L; CNS_D; and CNS_D + L (n = 5). The mice in each group were intravenously administered with 0.2 mL of PBS or 300 μg/mL CNS₀, CNS₉, CNS_J, and CNS_D. Each primary tumor was then photoirradiated using a 1064 nm laser (1 W cm⁻²) for 5 min at 24 h postinjection. After the different treatments, the treatment efficacies were assessed by calculating the volumes of both primary and distant tumors every two days for 14 days. Meanwhile, the body weights of 4T1 tumor-bearing Balb/c mice were also recorded every two days for 14 days. Tumor volume (V) was calculated using the formula: \( V = \text{length} \times \text{width}^2/2 \), and the relative tumor volumes were calculated as \( V/V_0 \) (where \( V_0 \) represents the original tumor volumes). On day 1 post-treatment, the tumors were examined for H&E staining to evaluate the intratumoral treatment effects.

The mice in the different treatment groups (n = 3) were euthanized to collect lung tissue at 30 days post-treatment to study the antitumor lung metastasis of CNS nanoparticles. The metastatic nodules in the lungs were photographed and H&E staining was performed.

**In vivo biocompatibility assessment of CNS₉**

Panc02 tumor-bearing C57BL/6 mice in each group were sacrificed at the end of treatment. Major organs including heart, liver, spleen, lung, and kidney were collected and examined by H&E staining. The long-term biocompatibility of CNS₉ was also assessed in healthy female C57BL/6 mice. The mice in the treated groups were intravenously injected with 200 μL of 300 μg/mL CNS₉. At day 0 and various post-injection time points (days 15 and 30), blood samples were examined for routine blood and biochemical analysis (n = 3). The corresponding major organs (heart, liver, spleen, lung, and kidney) were also examined by H&E staining at 0, 15, and 30 days.

**Statistical analysis**

Data are shown as mean ± standard deviation. One-way analysis of variance (ANOVA) with Tukey's multiple comparisons test was performed to analyze the statistical significance among different groups. Statistical significance was divided as three categories: *p < 0.05 **p < 0.01, and ***p < 0.001.

**Results And Discussion**

**Synthesis and characterization of CNS**

Various photoactivated CNS loading agents were prepared using a film hydration method[49]. In brief, a thin film composed of DPPC (MW = 734.0) and DSPE–PEG_{2k} (MW = 2805.5) with a feeding mass ratio of
25:5 was synthesized and then hydrated with ultrapure water including CuS, JQ1, and CpG. Hydrophobic JQ1 and hydrophilic CuS and CpG were encapsulated into temperature-responsive liposomes through hydrophobic and π–π stacking interactions. The EE of CNS\textsubscript{D} was 71.8% for CuS, 57.2% for JQ1, and 69.8% for CpG, and the corresponding LC values were 4.3%, 1.7%, and 0.1%, respectively. Three control counterparts (CNS\textsubscript{0}, CNS\textsubscript{C}, and CNS\textsubscript{J}) were simultaneously prepared using a similar process and used as a comparison.

As shown in the transmission electron microscopy (TEM) images, CNS\textsubscript{D} and the three control counterparts (CNS\textsubscript{0}, CNS\textsubscript{C}, and CNS\textsubscript{J}) were quasi-spherical and showed a uniform size distribution (Figure 1a). Dynamic light scattering (DLS) revealed that the hydrodynamic size of CNS\textsubscript{D} was approximately 31.3 ± 1.4 nm, which was slightly larger than that of CNS\textsubscript{0} (25.1 ± 1.1 nm), CNS\textsubscript{C} (27.0 ± 2.7 nm), and CNS\textsubscript{J} (26.2 ± 3.7 nm) (Figure 1b). Moreover, the polydispersity indexes (PDIs) of CNS\textsubscript{0}, CNS\textsubscript{C}, CNS\textsubscript{J}, and CNS\textsubscript{D} were 0.23, 0.22, 0.24, and 0.23, respectively, suggesting good mono-dispersity of the four types of nanoparticles. The zeta potential was measured to investigate the surface charge of various prepared nanoparticles. Compared with CNS\textsubscript{C} (-28.9 mV), CNS\textsubscript{D} (-23.4 mV) in 1× phosphate-buffered saline (PBS) showed an elevated surface charge, indicating successful JQ1 loading. Compared with CNS\textsubscript{J} (-20.9 mV), CNS\textsubscript{D} (-23.4 mV) in 1× PBS showed a reduced surface charge, indicating successful CpG ONDs encapsulation (Figure 1c). CNS\textsubscript{D} and the three control counterparts (CNS\textsubscript{0}, CNS\textsubscript{C}, and CNS\textsubscript{J}) showed similar peaks in the ultraviolet-visible (UV-vis) absorption spectrum, indicating the inappreciable affection of loaded two drugs on the optical property of the prepared nanoparticles (Figure 1d). Furthermore, the prepared CNS\textsubscript{D} nanoparticles showed excellent colloidal stability due to their stable hydrodynamic size and PDI over 10 days (Additional file 1: Figure S1).

**Photothermal properties and photothermal-induced drug release performance**

The NIR-II photothermal properties and photothermal-induced release of immune agents from CNS were further investigated. Under conditions of photoirradiation (1064 nm) at a power intensity of 1 W cm\textsuperscript{-2}, the temperatures of CNS\textsubscript{0}, CNS\textsubscript{C}, CNS\textsubscript{J}, and CNS\textsubscript{D} solution showed an obvious increase up to around 55°C in 7 min (Figure 1e, Additional file 1: Figure S2). The photothermal temperature curves exhibited minimal differences after five cycles of heating and natural cooling (Figure 1f), showing good photothermal stability of the nanoparticles. Furthermore, the photothermal conversion efficiency of CNS\textsubscript{D} was ≈ 32.6%, which was similar to that of CNS\textsubscript{0} (32.4%), CNS\textsubscript{C} (31.8%), and CNS\textsubscript{J} (31.5%) (Additional file 1: Figure S3).

The photo-triggered release properties of the loaded immune agents were further analyzed. Under conditions of photoirradiation (1064 nm) at a power intensity of 1 W cm\textsuperscript{-2} for 5 min, the cumulative release of JQ1 from CNS\textsubscript{D} was 42.3% in 1 h, which was 3.6-fold higher than that without laser irradiation (Figure 1g). The underlying mechanism can be explained as follows: CNS\textsubscript{D} mediated the photothermal effect and induced the dissociation of temperature-responsive liposomes with a phase-transition temperature of around 42 °C, resulting in the on-demand release of JQ1.
CNS-mediated intracellular photothermal-activated immune response

The cellular uptake of CNS was first analyzed in Panc02 cells. The cellular uptake of CNS was confirmed by loading 2.5% (w/w) CNS with indocyanine green (ICG), which is a cyanine dye approved by the FDA, to construct four loaded CNS nanoparticles (CNS$_D@$ICG, CNS$_C@$ICG, CNS$_J@$ICG, and CNS$_D@$ICG) ([Additional file 1: Figure S4]). The ICG-loaded CNS nanoparticles exhibited identical peaks in the UV-vis absorption spectrum, indicating their successful preparation ([Additional file 1: Figure S5]). After a 24-h incubation, the fluorescence intensity of CNS$_D$-cultured Panc02 cells was 105-fold greater than that of the control group, suggesting the effective internalization of nanoparticles into Panc02 cells. There was no obvious difference in fluorescence intensity in Panc02 cells cultured with the four nanoparticles ([Figure 2a and b]). The cytotoxicity of these CNS nanoparticles was analyzed. The viability of the Panc02 cells was >90% after incubation with four CNS nanoparticles for 24 h, indicating the nontoxicity and good biocompatibility of CNS in vitro ([Figure 2c]). The capacity for CNS to suppress tumor cells was further assessed. After incubation with CNS$_D$, CNS$_C$, CNS$_J$, or CNS$_D$ for 24 h, Panc02 cells were exposed to a 1064 nm NIR laser at a power density of 1 W cm$^{-2}$ for 5 min. The results showed that cells treated with diverse CNS nanoparticles plus NIR-II light all decreased with elevating CuS concentrations ([Figure 2c]). Using 100 $\mu$g/mL CuS, the viabilities of the Panc02 cells treated with CNS$_0$ + L, CNS$_C$ + L, CNS$_J$ + L, and CNS$_D$ + L decreased to 24.6%, 38.7%, 17.3%, and 11.9%, respectively, suggesting excellent CNS-mediated photothermal effects against cell growth.

Exposure of the tumor cells to calreticulin (CRT) as a specific signal for triggering APCs was a characteristic sign of ICD induction. Thus, CRT exposure of the Panc02 cells was further evaluated to validate the performance of CNS-mediated ICD under conditions of NIR-II irradiation in vitro. After NIR-II laser irradiation for 24 h, the mean fluorescence intensity (MFI) of CRT in Panc02 cells treated with the four CNS nanoparticles was elevated. Of note, the MFI of CRT in the CNS$_D$ + L group was 3.2 and 2.5-fold higher than that in the control and CNS$_D$ groups, respectively ([Additional file 1: Figure S6]). These data indicate that CNS nanoparticles were capable of efficiently triggering ICD under conditions of NIR-II laser irradiation.

As a key role in human immunity, immature DCs can engulf antigens and transfer them to neighboring lymph nodes, where they are processed into peptides for T cell activation. Mature DCs can be detected by the co-stimulatory molecules, CD80/CD86, which are representative markers that signify DC maturation. Murine bone marrow-derived dendritic cells (BMDCs) extracted from C57 mice received different treatments and the corresponding percentages of matured DCs (CD11c$^+$CD80$^+$CD86$^+$) were then measured by flow cytometry ([Figure 2d]). NIR-II laser irradiation significantly elevated the maturation of various CNS-treated DCs compared with the non-laser irradiation group ([Figure 2e]). DC maturation in the CNS$_D$ + L group was 26.4-fold higher than in the PBS group. Notably, DC maturation in the CNS$_D$ + L group was 3.7, 2.0, and 1.8-fold higher than that of the CNS$_D$, CNS$_0$ + L, and CNS$_J$ + L groups, respectively, suggesting that the NIR-mediated photothermal effect can be attributed to the laser-induced release of tumor antigens and loaded immune-agents ([Figure 2f]). However, DC maturation was similar in
the CNS\textsubscript{D} + L and CNS\textsubscript{C} + L groups, which may be explained by the fact that JQ1 does not directly facilitate DC maturation.

Immune-related cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), can be secreted by mature DCs. Thus, we measured the concentration of cytokines in the medium using ELISA kits. The secretion levels of TNF-\(\alpha\) and IL-6 in the NIR-II laser-treated CNS groups were all increased (Figure 2g and h). In particular, levels of IL-6 and TNF-\(\alpha\) in the CNS\textsubscript{D} + L group were 2.0- and 1.6-fold, respectively, higher than that of the CNS\textsubscript{D} group.

**CNS-mediated synergistic NIR-II photothermal immunotherapy in Panc02 tumors**

Panc02 tumor-bearing C57BL/6 mice with primary and distant tumors were used to evaluate the curative effect of CNS-mediated NIR-II photothermal immunotherapy in living mice. The mice were intravenously administered with various CNS nanoparticles and the primary tumor was then exposed to NIR-II laser treatment. The growth of primary and distant tumors was subsequently monitored for two weeks (Figure 3a). The ICG labeled CNS nanoparticles were intravenously injected into the Panc02 tumor-bearing mice to investigate the optimal tumor accumulation of CNS. The fluorescence intensity in tumors of CNS\textsubscript{D}, CNS\textsubscript{C}, CNS\textsubscript{J}, and CNS\textsubscript{D}-treated mice gradually increased and peaked at 24 h post-injection (Additional file 1: Figure S7a). At this time-point, the intensity of the tumors of CNS-injected mice was at least 5.9-fold higher relative to the background, demonstrating the accumulation of nanoparticles into tumors (Additional file 1: Figure S7b).

The photothermal properties of CNS nanoparticles were further investigated in both Panc02- and 4T1 tumor-bearing mice to examine the effects of PTT in vivo. At 24 h post-treatment using various CNS nanoparticles, the primary tumors of the mice were exposed to the NIR-II laser (1064 nm) at a power intensity of 1 \(\text{W cm}^{-2}\) for 5 min. The temperatures of the region of Panc02 tumors in all CNS-treated groups were gradually elevated and peaked at least \(\approx 54.8^\circ\text{C}\) for 5 min post-irradiation (Figure 3b and c). Similarly, the temperatures of the region of 4T1 tumors in all treated groups were at least \(\approx 54.2^\circ\text{C}\) for 5 min post-irradiation (Additional file 1: Figure S8). These results showed that the CNS nanoparticles have good photothermal properties in vivo. Furthermore, the tumor temperatures in all treated groups were similar at the same time points, showing that all CNS nanoparticles possessed similar photothermal conversion efficiencies and intratumoral aggregation.

Due to the good photothermal conversion efficiency and excellent intratumoral aggregation properties of CNS nanoparticles, Panc02 tumor-bearing mice were then randomly divided into six groups to investigate the antitumor capacities of various CNS nanoparticles. After treatment, the curative effects of CNS in vivo were assessed by monitoring the growth of the primary and distant tumors. In the absence of photoirradiation, the growth of primary and distant tumors in CNS\textsubscript{D} and PBS-treated mice showed negligible inhibition (Figure 3d and e). Following photoirradiation, the primary tumor volume in the CNS\textsubscript{D}-treated group was effectively suppressed and was 6.7, 4.1, and 3.2-fold lower than CNS\textsubscript{D}, CNS\textsubscript{C}, and CNS\textsubscript{J}-treated mice, respectively. The distant tumor volume in the CNS\textsubscript{D}-treated group was also effectively
inhibited and was 3.0, 2.4, and 3.1-fold lower than CNS0, CNSC, and CNSJ-treated mice, respectively. Furthermore, the tumor weights of the primary and distant tumors in the CNSD + L group were 0.06 and 0.2 g, which was 25.7 and 6.6-fold lower than that in the CNSD group, respectively (Figure 3f). The pathological data from the CNSD + L group exhibited larger regions of cell apoptosis and necrosis [hematoxylin and eosin (H&E) and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)] in the primary tumors compared with the CNS0 + L, CNSC + L, and CNSJ + L groups (Figure 3g). The PBS and CNSD groups showed no obvious areas of apoptosis in these masses. Similarly, Ki-67 staining images showed the greatest inhibition of cancer cell proliferation in the CNSD + L group.

**CNS-mediated synergistic NIR-II photothermal immunotherapy on 4T1 tumors**

4T1 tumor-bearing Balb/c mice with primary and distant tumors were given various treatments and monitored to investigate the efficacy of CNS nanoparticles-mediated photothermal immunotherapy in inhibiting lung metastasis (Figure 4a). The inhibition effects of both primary and distant tumors were investigated due to the desirable photothermal effects of CNS nanoparticles in 4T1 tumor-bearing mice. In contrast to the results of the Panc02 tumor-bearing mouse model, the growth of primary and distant tumors was not suppressed in the control and CNSD groups. However, photoirradiation showed the greatest suppressive effects of both primary and distant tumors in CNSD-treated mice compared with CNS0, CNSC, and CNSJ-treated mice (Figure 4b and c). Compared with the other groups, the CNSD + L group exhibited the most apoptosis of tumor cells, as demonstrated by the H&E staining of the tumor biopsy (Figure 4e). The lungs of the 4T1 tumor-bearing mice were extracted and pathologically examined 30 days after various treatments to investigate the therapeutic effects of CNS-mediated inhibition of lung metastasis (Figure 4d and f). The greatest inhibitory effect of tumor lung metastasis was observed in CNSD-treated mice. Furthermore, the average number of pulmonary metastasis in the CNSD + L group was at least six times lower than that in the other groups. These data showed that CNSD nanoparticles possessed the potential to inhibit diverse malignant tumors and prevent tumor metastasis.

**CNS-mediated synergistic immune response *in vivo***

The mechanisms of CNS-mediated photothermal immune response *in vivo* were further evaluated due to the superior suppression of primary tumors and metastatic tumors.

An in-depth analysis of the key processes of the immune response *in vivo*, including ICD induction, DC maturation, and T cell infiltration, was performed to investigate the CNS-based photothermal immune-activation and the synergic effects. Since the induction of ICD is the first step in photothermal immune activation, activation of ICD triggered by CNS nanoparticles under laser irradiation was analyzed first. The representative biomarkers of ICD including adenosine triphosphate (ATP), CRT, and expression of high mobility group box 1 protein (HMGB1) were used to facilitate the uptake, processing, and presentation of tumor antigens in DCs. One day after treatment, the intratumoral ATP levels of various CNS nanoparticles plus laser irradiation were elevated and compared with the single PBS-treated and CNSD-treated groups.
The ATP levels of the CNS\(_D + L\) group were 2.2 and 1.8-fold higher than those of the control and CNS\(_D\) groups, respectively (Figure 5a). Moreover, there was a negligible difference in intratumoral ATP levels between the four CNS nanoparticles with photoirradiation, showing that ATP was mainly influenced by NIR-irradiated CNS nanoparticles. Immunohistochemical staining of the tumor section revealed CRT in the tumors as a brown signal. Almost no obvious brown signal was shown in the tumors after treatment with CNS\(_D\) alone or PBS (Figure 5b). In contrast, tumors treated with various CNS nanoparticles with photoirradiation exhibited an obvious enhanced brown signal. HMGB1 was shown as a red fluorescent signal in the immunofluorescence staining images. Similarly, compared with the CNS\(_D\) alone and PBS-treated groups, tumors treated with diverse CNS nanoparticles with photoirradiation exhibited significantly enhanced red fluorescence signals (Figure 5c). These data suggested that CNS-mediated NIR-II PTT was able to induce intratumoral ICD.

The tumor-draining lymph nodes in C57BL/6 mice were collected after treatment and measured using flow cytometry to evaluate DC maturation (CD11c\(^+\)CD80\(^+\)CD86\(^+\)) (Additional file 1: Figure S9). The percentage of matured DCs in CNS\(_D\)-treated mice with laser irradiation was the highest, and was 2.4, 2.1, and 1.6-fold higher than that in the control, CNS\(_D\), and CNS\(_C + L\) groups, respectively, suggesting that CNS-mediated hyperthermia could activate DCs maturation via the synergic action of PTT-induced ICD and the photothermal-induced release of immune-agents (Figure 5d and e). Since JQ1 facilitates the downregulation of PD-L1 expression, we examined whether NIR-II laser-induced JQ1 released from CNS\(_D\) could suppress PD-L1 expression in Panc02 tumor xenografts in vivo by examining immunohistochemical staining of the tumor section. As shown in the representative immunohistochemistry staining images, the brown signal intensity in the CNS\(_D + L\) and CNS\(_C + L\) groups was significantly weaken compared with those in the other treatment groups (Figure 5f). The brown signal intensity in the CNS\(_D\) group without photoirradiation did not decrease compared with that in the CNS\(_D\) group with photoirradiation, implying that tumor PD-L1 expression decreased due to NIR laser-induced JQ1 release from CNS\(_D\) nanoparticles.

Cytotoxic T lymphocytes, such as CD8\(^+\) T cells, can identify and kill tumor cells[50]. Hence, tumor tissues were collected after various treatments to assess the percentage of cytotoxic T lymphocytes cells (CD8\(^+\)/CD3\(^+\)) via flow cytometric analysis to investigate the CNS-mediated synergized antitumor immune response (Additional file 1: Figure S10). Levels of CD8\(^+\) T cells in various CNS nanoparticles-treated mice were all increased after photoirradiation compared with those without photoirradiation. In particular, the percentages of T cells (CD8\(^+\)/CD3\(^+\)) in the CNS\(_D + L\) group were 1.6, 1.2, and 1.2-fold higher than those in the CNS\(_0 + L\), CNS\(_C + L\), and CNS\(_J + L\) groups, respectively (Figure 5g and h). Similarly, immunofluorescence analysis revealed a greater red fluorescence intensity in the CNS\(_D + L\) group for CD8 than that in other groups, which is in keeping with the flow cytometry results (Figure 5i). These results indicated that CNS\(_D\)-mediated photothermal immunotherapy enabled the acquisition of synergetic antitumor immune response by combining the photothermally released immunoregulators and photothermal-induced immune response. Furthermore, the secretion of cytokines, such as IL-6, TNF-\(\alpha\), and
interferon-gamma (IFN-γ), is a key indicator of an antitumor immune response[22]. Therefore, the levels of these cytokines in the serum of Panc02 tumor-bearing C57BL/6 mice were also investigated by ELISA. The levels of IL-6, TNF-α, and IFN-γ in the CNS_D + L group were the highest and were 1.3, 1.2, and 1.2-fold higher than those in other groups (Figure 5j–l).

**Gene expression analysis in vivo**

Transcriptomics analysis of CNS_D and PBS-treated mice was conducted to thoroughly investigate the mechanisms of immune activation at the genetic level in vivo. Analysis of immune-related genes across the whole genome revealed a total of 75 differentially expressed immune-related genes, among which, 57 were upregulated and 18 were downregulated (Additional file 1: Figure S11). These differentially expressed immune-related genes were depicted in the heat map (Figure 6a). Among the upregulated immune-related expressed genes, gene ontology (GO) process analyses and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were further performed to determine biological information, such as regulation pathway and biomolecular function. GO process analyses showed that the most enriched pathways included immune response, immune system response, cytokine-mediated signaling pathway, and regulation of immune response, which are closely related to immune activation (Figure 6b). KEGG pathway analyses also indicated that several immune activation-related pathways, including Toll-like receptor signaling pathway and IL-17 signaling pathway, were enriched in CNS_D-treated mice (Figure 6c). In the CNS_D-treated groups, several upregulated genes, including Tnf, Irf7, Jun, Ccl3, and Ccl4, were associated with the Toll-like receptor signaling pathway, which plays a major role in proinflammatory cytokine-induced DC maturation, implying that combined CNS_D and laser irradiation treatment may reawaken the antitumor immune response in the immunosuppressive tumor microenvironment[51, 52].

**Biocompatibility of CNS nanoparticles in vivo**

The biocompatibility and biotoxicity of CNS nanoparticles were evaluated in vivo. No obvious behavioral abnormalities or weight loss were observed during the treatment of both 4T1 tumor-bearing Balb/c mice and Panc02 tumor-bearing mice (Additional file 1: Figure S12, 13). Moreover, after treatment, H&E staining images showed that regions with necrosis or apoptosis were rarely detected in the murine major organs, including heart, liver, spleen, lung, and kidney in the different treatment groups (Additional file 1: Figure S14, 15). Additionally, analysis of long-term biotoxicity in C57BL/6 mice revealed no significant differences in diversely vital blood parameters, and liver and kidney function indexes among the Control, D15, and D30 groups (Additional file 1: Figure S16). The corresponding histological morphology in the H&E staining images remained normal at different treatment points (Control, D15, and D30). These results indicated the perfect biocompatibility of CNS nanoparticles for tumor immunotherapy in vivo.

**Conclusion**

In conclusion, in the present study, a spatiotemporally controllable CNS nanoparticle was developed to achieve NIR-II photothermal-synergized immunotherapy via remotely photoactivated release of immune
agents in specific areas. The CNS\textsubscript{D} nanoparticles possessed a satisfactory photothermal conversion efficiency ($\approx 32.6\%$) and enabled the effective accumulation in the murine tumor tissues after systemic administration. Under conditions of NIR-II photoirradiation, CNS\textsubscript{D} rapidly elevated the localized temperature, leading to tumor ablation and induction of ICD, and precisely melted the protective lipid layer to release two antitumor immune agents in the tumor region. Levels of matured DCs and CD8\textsuperscript{+} T cells in CNS\textsubscript{D}-treated mice were increased by 2.4 and 2.3-fold, respectively, compared with those in the control group. Therefore, prepared CNS nanoparticles-mediated photothermal-synergized immunotherapy radically suppressed tumor growth in two types of murine models and also effectively inhibit pulmonary metastasis, suggesting a potentially novel strategy for safe and efficient photoactivated immunotherapy.

**Abbreviations**

NIR-II: second near-infrared; CuS: copper sulfide; TLR-9: toll-like receptor-9; PD-L1: programmed death-ligand 1; ICD: immunogenic cell death; ICBs: immune checkpoint inhibitors; PD-1: programmed death 1; PD-L1: programmed death ligand 1; CTLA-4: cytotoxic T lymphocyte-associated protein 4; FDA: Food and Drug Administration; PTT: photothermal therapy; DAMPs: damage-associated molecular patterns; DCs: dendritic cells; MPE: maximum permissible exposure; TLR-9: toll-like receptor-9; DPPC: 1,2-dipalmitoyl-sn-glycerol-3-phosphocholine; DSPE–PEG\textsubscript{2k}: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol)\textsubscript{2000}; APCs: antigen-presenting cells; ANOVA: one-way analysis of variance; EE: encapsulation efficiency; LC: loading capacity; TEM: transmission electron microscopy; DLS: dynamic light scattering; PBS: phosphate-buffered saline; UV-vis: ultraviolet-visible; ICG: indocyanine green; CRT: calreticulin; MFI: mean fluorescence intensity; BMDCs: bone marrow-derived dendritic cells; IL-6: interleukin-6; TNF-\alpha: tumor necrosis factor-\alpha; H&E: hematoxylin and eosin; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling; ATP: adenosine triphosphate; HMGB1: high mobility group box 1 protein; IFN-\gamma: interferon-gamma; GO: gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes;

**Declarations**

**Ethics approval and consent to participate**

All animal experimental procedures were approved by the Ethical Committee of Zhongshan Hospital of Fudan University (B2019-136R2).

**Competing interests**

All authors declare that they have no competing interests.
Funding

This work was supported by the Shanghai Municipal Key Clinical Specialty (shs1czdsk03202) and the Opening Project of State Key Laboratory of High-Performance Ceramics and Superfine Microstructure (SKL201908SIC).

Authors’ contributions

SHT and YTZ participated all experiments and date analyzing. SHT and LX contributed to manuscript preparation and writing. LX, LYY, LJK, LY, and PPK contributed to data curration and data analyzing. PPK, LY and WXH contributed to cell experiment and animal experiment. NDL, PPK, LY, WXH, WXL contributed to project design, and supervision; SHT, LY, and WXL contributed to funding acquisition. LX, NDL, LY, WXL, WXH, and PPK contributed to the manuscript review. All authors read and approved the final manuscript.

Acknowledgements

We appreciate Prof. Mengsu Zeng (Department of Radiology, Zhongshan Hospital, Fudan University) for the administrative and funding assistance in the experiment.

References

1. Bader JE, Voss K, Rathmell JC. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol Cell. 2020;78:1019–33.
2. Feng M, Jiang W, Kim B, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019;19:568–86.
3. Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17:129.
4. Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495–9.
5. Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:155.
6. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.
7. Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunol Rev. 2019;290:127–47.
8. O’Donnell JS, Teng M, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151–67.
9. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62–8.

10. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8.

11. Balachandran VP, Beatty GL, Dougan SK. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. Gastroenterology. 2019;156:2056–72.

12. Bader JE, Voss K, Rathmell JC. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol Cell. 2020;78:1019–33.

13. Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol. 2020;20:321–34.

14. Chmielewski M, Abken H. CAR T cells transform to trucks: chimeric antigen receptor-rediredcted T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother. 2012;61:1269–77.

15. Wang X, Walter M, Urak R, Weng L, Huynh C, Lim L, et al. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res. 2018;24:106–19.

16. Chan WK, Suwannasaen D, Throm RE, Li Y, Eldridge PW, Houston J, et al. Chimeric antigen receptor-rediredcted CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity. Leukemia. 2015;29:387–95.

17. Shi Y, Lammers T. Combining Nanomedicine and Immunotherapy. Accounts Chem Res. 2019;52:1543–54.

18. Zhang P, Zhai Y, Cai Y, Zhao Y, Li Y. Nanomedicine-Based Immunotherapy for the Treatment of Cancer Metastasis. Adv Mater. 2019;31:1904156.

19. van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJM, Lammers T. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14:1007–17.

20. Duan X, Chan C, Lin W. Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy. Angew Chem Int Ed Engl. 2019;58:670–80.

21. Šamec N, Zottel A, Videtič PA, Jovčevska I. Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma. Molecules. 2020;25.

22. Li J, Yu X, Jiang Y, He S, Zhang Y, Luo Y, et al. Second Near-Infrared Photothermal Semiconducting Polymer Nanoadjuvant for Enhanced Cancer Immunotherapy. Adv Mater. 2020;2003458.

23. Yong SB, Chung JY, Song Y, Kim J, Ra S, Kim YH. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells. Biomaterials. 2019;219:119401.

24. Muraoka D, Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I, et al. Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. J Clin Invest. 2019;129:1278–94.
25. Li S, Bennett ZT, Sumer BD, Gao J. Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles. Acc Chem Res. 2020;53:2546–57.

26. Zeng Z, Zhang C, Li J, Cui D, Jiang Y, Pu K. Activatable Polymer Nanoenzymes for Photodynamic Immunometabolic Cancer Therapy. Adv Mater. 2021;33:2007247.

27. Wei P, Cornel EJ, Du J. Ultrasound-responsive polymer-based drug delivery systems. Drug Deliv Transl Res. 2021;11:1323–39.

28. Yu B, Choi B, Li W, Kim D. Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy. Nat Commun. 2020;11:3637.

29. Chu H, Zhao J, Mi Y, Di Z, Li L. NIR-light-mediated spatially selective triggering of anti-tumor immunity via upconversion nanoparticle-based immunodevices. Nat Commun. 2019;10:2839.

30. Li X, Lovell JF, Yoon J, Chen X. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat Rev Clin Oncol. 2020;17:657–74.

31. Liu Y, Bhattarai P, Dai Z, Chen X. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem Soc Rev. 2019;48:2053–108.

32. Jiang Q, Liu Y, Guo R, Yao X, Sung S, Pang Z, et al. Erythrocyte-cancer hybrid membrane-camouflagged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors. Biomaterials. 2019;192:292–308.

33. Li W, Yang J, Luo L, Jiang M, Qin B, Yin H, et al. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat Commun. 2019;10:3349.

34. Peng J, Xiao Y, Li W, Yang Q, Tan L, Jia Y, et al. Photosensitizer Micelles Together with IDO Inhibitor Enhance Cancer Photothermal Therapy and Immunotherapy. Adv Sci (Weinh). 2018;5:1700891.

35. Chen Q, Xu L, Liang C, Wang C, Peng R, Liu Z. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun. 2016;7:13193.

36. Wang T, Wang D, Yu H, Feng B, Zhou F, Zhang H, et al. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. Nat Commun. 2018;9:1532.

37. Huang L, Li Y, Du Y, Zhang Y, Wang X, Ding Y, et al. Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy. Nat Commun. 2019;10:4871.

38. Zhang X, An L, Tian Q, Lin J, Yang S. Tumor microenvironment-activated NIR-II reagents for tumor imaging and therapy. J Mater Chem B. 2020;8:4738–47.

39. Liu P, Wang Y, An L, Tian Q, Lin J, Yang S. Ultrasmall $\text{WO}_3 - x@gamma$-poly-$l$-glutamic Acid Nanoparticles as a Photoacoustic Imaging and Effective Photothermal-Enhanced Chemodynamic Therapy Agent for Cancer. ACS Appl Mater Interfaces. 2018;10:38833–44.

40. Zhang Q, Guo Q, Chen Q, Zhao X, Pennycook SJ, Chen H. Highly Efficient 2D NIR-II Photothermal Agent with Fenton Catalytic Activity for Cancer Synergistic Photothermal–Chemodynamic Therapy.
41. Liu G, Zhu J, Guo H, Sun A, Chen P, Xi L, et al. Mo$_2$C-Derived Polyoxometalate for NIR-II Photoacoustic Imaging-Guided Chemodynamic/Photothermal Synergistic Therapy. Angew Chem Int Ed Engl. 2019;58:18641–6.

42. Ma Y, Zhang Y, Li X, Zhao Y, Li M, Jiang W, et al. Near-Infrared II Phototherapy Induces Deep Tissue Immunogenic Cell Death and Potentiates Cancer Immunotherapy. ACS Nano. 2019;13:11967–80.

43. Li Y, Liu X, Pan W, Li N, Tang B. Photothermal therapy-induced immunogenic cell death based on natural melanin nanoparticles against breast cancer. Chem Commun. 2020;56:1389–92.

44. Gao G, Jiang YW, Guo Y, Jia HR, Cheng X, Deng Y, et al. Enzyme-Mediated Tumor Starvation and Phototherapy Enhance Mild-Temperature Photothermal Therapy. Adv Funct Mater. 2020;30:1909391.

45. Zhen X, Xie C, Jiang Y, Ai X, Xing B, Pu K. Semiconducting Photothermal Nanoagonist for Remote-Controlled Specific Cancer Therapy. Nano Lett. 2018;18:1498–505.

46. Wei H, Zhao Z, Wang Y, Zou J, Lin Q, Duan Y. One-Step Self-Assembly of Multifunctional DNA Nanohydrogels: An Enhanced and Harmless Strategy for Guiding Combined Antitumor Therapy. ACS Appl Mater Inter. 2019;11:46479–89.

47. Deng C, Zhang Q, Jia M, Zhao J, Sun X, Gong T, et al. Tumors and Their Microenvironment Dual-Targeting Chemotherapy with Local Immune Adjuvant Therapy for Effective Antitumor Immunity against Breast Cancer. Adv Sci (Weinh). 2019;6:1801868.

48. Tian Y, Wang X, Zhao S, Liao X, Younis MR, Wang S, et al. JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer. ACS Appl Mater Interfaces. 2019;11:46626–36.

49. Sun H, Feng M, Chen S, Wang R, Luo Y, Yin B, et al. Near-infrared photothermal liposomal nanoantagonists for amplified cancer photodynamic therapy. J Mater Chem B. 2020;8:7149–59.

50. Zhou F, Gao J, Xu Z, Li T, Gao A, Sun F, et al. Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer. Nano Today. 2021;36:101025.

51. O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7:353–64.

52. Kawai T, Akira S. TLR signalling. Semin Immunol. 2007;19:24–32.

Figures
Figure 1

a) Typical TEM images of CNS0, CNSJ, CNSC, and CNSD. b) Typical DLS profiles of CNS0, CNSJ, CNSC, and CNSD. c) Zeta potentials of CNS0, CNSJ, CNSC, and CNSD. d) UV-vis absorption spectra of CNS0, CNSJ, CNSC, and CNSD. e) Photothermal effect of 100 µg/mL CNS0, CNSJ, CNSC, and CNSD with 1064-nm irradiation (1 W cm⁻²) followed by laser shut-off. f) Photothermal stability assay of CNS0, CNSJ, CNSC, and CNSD after five cycles of laser on/off. g) Release of JQ1 from CNSD with or without laser irradiation (1064-nm, 1 W cm⁻²) for 5 min (the concentrations of CuS and JQ1 for CNSD were 100 and 79.1 µg/mL, respectively).
Figure 2

a) Fluorescence intensity of Panc02 cells treated with PBS (control) or various ICG-loaded CNS nanoparticles ([ICG] = 20 μg mL⁻¹) for 24 h via flow cytometry. b) Corresponding relative ICG fluorescence intensity of Panc02 cells after treatment with PBS (control) or various ICG-loaded CNS nanoparticles ([ICG] = 20 μg mL⁻¹) for 24 h via flow cytometry (n = 3). c) Cell viabilities of Panc02 cells after treatment with various types of CNS at different concentrations (0, 12.5, 25, 50 and 100 μg/mL) with or without 1064-nm laser illumination (1 W cm⁻²) for 5 min. d) Schematic illustration of CNS-induced DCs maturation in vitro. e) Flow cytometry assay of mature DCs (CD11c⁺CD80⁺CD86⁺) in the different
a) Schematic illustration of Panc02 tumor implantation, treatment, and monitoring. b) NIR thermal photos of Panc02 tumor-bearing mice under laser irradiation at 24 h post-injection of 200 μL of PBS
(control), or 300 µg/mL CNS0, CNSC, CNSJ, or CNSD via tail-vein injection. c) Temperature increase curves in the tumor areas of Panc02 tumor-bearing mice after administration of PBS (control), CNS0, CNSC, CNSJ, and CNSD under NIR-II laser illumination (1064 nm, 1W cm−2, 5 min). d, e) Relative tumor volumes of primary mass (d) and distant masses (e) in Panc02 tumor-bearing C57BL/6 mice (n = 5) intravenously administered with 200 µL of PBS or 300 µg/mL CNS0, CNSC, CNSJ, or CNSD in the presence and absence of photoirradiation. f) The tumor weight of primary masses and distant masses in the Panc02 tumor-bearing C57BL/6 mice (n = 5) in the control, CNS0, CNSC, CNSJ, and CNSD groups at the end of treatments. g) The representative H&E, TUNEL, and Ki67 immunofluorescence staining images of primary tumors in various groups (the scale bar represents 50 µm). * p < 0.05, *** p < 0.001.
Figure 4

a) Schematic illustration of 4T1 tumor implantation, treatment, and monitoring. b, c) Relative tumor volumes of primary masses (b) and distant masses (c) in 4T1 tumor-bearing Balb/c mice (n = 5) intravenously administered with 0.2 mL of PBS (control) or 300 μg/mL CNS0, CNSC, CNSJ, or CNSD. d) Metastatic nodules of the lung in the various groups. e) H&E staining of the 4T1 tumors at day 1 after various treatments (the scale bar represents 50 μm). f) Digital photos of murine lung tissues and the corresponding H&E staining of the lung tissues at the end of treatments (n = 3, the scale bar represents 50 μm). **p < 0.01 and ***p < 0.001.
Figure 5

NIR-II photoactivated immune activation in vivo. a) Intratumoral levels of ATP in Panc02tumor-bearing C57BL/6 mice in the different groups after intravenous injection of 200 µL of PBS or 300 µg mL-1 CNS0, CNSc, CNSJ, or CNSD. b) Immunohistochemical staining photos of CRT in tumors sections with different treatments at day 1 post-treatment (blue signal represents cell nuclei and brown signal represents CRT; the scale bar represents 100 µm). c) Immunofluorescence staining photos of HMGB1 in tumor sections
with different treatments at day 1 post-treatment (blue signal represents cell nuclei and brown signal represents HMGB1; the scale bar represents 50 μm). d, e) Flow cytometric plots (d) and corresponding quantitative percentages (e) of matured DCs (CD80+CD86+ gated on CD11c+) in tumor-draining lymph nodes of Panc02 tumor-bearing C57BL/6 mice in various groups at day 3 post-treatment. f) Immunohistochemical staining photos of PD-L1 in tumors sections with different treatments at day 14 post-treatment (blue signal represents cell nuclei and brown signal represents PD-L1; the scale bar represents 100 μm). g, h) Flow cytometric plots (g) and corresponding quantitative percentages (h) of CD3+/CD4+ T cells and CD3+/CD8+ T cells in distant tumors of Panc02 tumor-bearing C57BL/6 mice in various groups at day 10 post-treatment. i) Immunofluorescence staining of CD8 in tumors sections with different treatments at day 10 post-treatment (blue signal represents cell nuclei and brown signal represents HMGB1; the scale bar represents 50 μm). j–l) Serum levels of cytokines including IL-6 (j), TNF-α(k), and IFN-γ (l) in Panc02 tumor-bearing C57BL/6 mice in various groups at day 3 post-treatment. *p < 0.05, **p < 0.01, and ***p < 0.001.
a) Heat maps showing differential gene expression for screening immune function-related genes. b,c) GO enrichment analysis (b) and KEGG enrichment analysis (c) of differentially upregulated genes associated with the immune process, with the 20 most significantly enriched categories listed.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- TOC.jpg
- SupportinginformationJNB.docx